Immitra Bio is developing scalable, one-time curative in-vivo gene editing therapies built around a mutation-agnostic editing approach and a digital target discovery platform. Its lead candidate, IB-003, is being developed as a potential one-time curative in-vivo gene editing treatment for an inherited anemia. The company's approach is designed to avoid complex ex-vivo cell manipulation, patient conditioning, and stem cell transplantation, aiming to enable off-the-shelf formulations that treat all patients within a given disease regardless of underlying mutation. Immitra Bio says its platform could generate dozens of differentiated therapeutic assets more quickly than highly personalized approaches. The recent CHF 2.4 million pre-seed financing will primarily fund preclinical proof-of-concept work for IB-003 and support additional discovery and validation across the pipeline and platform refinement. The company highlights scalability and commercial viability as core objectives for its technology.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026